Breast cancer drug combo safety study ends early – only 4 patients enrolled
NCT ID NCT04967248
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was an observational study that planned to track side effects, especially high blood sugar, in patients taking alpelisib (Piqray) plus fulvestrant for a type of advanced breast cancer. It included postmenopausal women and men whose cancer had a specific gene mutation (PIK3CA) and had worsened after hormone therapy alone. However, the study was terminated early after enrolling only 4 participants, so it provides very limited information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alpelisib (Piqray) and fulvestrant
What this could lead to
If successful, this study could provide real-world safety data on alpelisib combined with fulvestrant for advanced breast cancer patients.
What could go wrong
The study was terminated early with only 4 participants, so results are very limited and may not be reliable or generalizable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.